Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8ZMG

Crystal structure of an inverse agonist antipsychotic drug pimavanserin-bound 5-HT2A

This is a non-PDB format compatible entry.
Summary for 8ZMG
Entry DOI10.2210/pdb8zmg/pdb
Descriptor5-hydroxytryptamine receptor 2A,Soluble cytochrome b562, Pimavanserin (2 entities in total)
Functional Keywordsclass a g protein-coupled receptor, inverse agonist, membrane protein
Biological sourceHomo sapiens (human)
More
Total number of polymer chains2
Total formula weight94067.70
Authors
Oguma, T.,Asada, H.,Sekiguchi, Y.,Imono, M.,Iwata, S.,Kusakabe, K. (deposition date: 2024-05-23, release date: 2024-08-28, Last modification date: 2024-10-09)
Primary citationOguma, T.,Jino, K.,Nakahara, K.,Asada, H.,Fuchino, K.,Nagatani, K.,Kouki, K.,Okamoto, R.,Takai, N.,Koda, K.,Fujita, S.,Sekiguchi, Y.,Yasuo, K.,Mayumi, K.,Abe, A.,Imono, M.,Horiguchi, N.,Iwata, S.,Kusakabe, K.I.
Dual 5-HT 2A and 5-HT 2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis.
J.Med.Chem., 67:14478-14492, 2024
Cited by
PubMed Abstract: Psychosis is a distressing symptom commonly occurring in people with dementia. To treat Parkinson's disease psychosis, pimavanserin (), a 5-HT receptor inverse agonist having minimal 5-HT receptor affinity and no dopamine D receptor affinity, was approved in the United States, but not for dementia-related psychosis due to limited efficacy issues. Herein, we report on the identification of a potent and dual 5-HT and 5-HT receptor inverse agonist having minimal hERG inhibition, after having demonstrated the involvement of both 5-HT and 5-HT receptors to deliver antipsychotic efficacy in an MK-801-induced locomotor model and having conducted 5-HT and 5-HT occupancy studies including a surrogate method. The introduction of a spirocyclopropyl group boosting 5-HT affinity in followed by further optimization to control lipophilicity resulted in balanced dual potency and metabolic stability, and mitigating hERG inhibition led to that showed significant antipsychotic efficacy due to the involvement of both receptors.
PubMed: 39137033
DOI: 10.1021/acs.jmedchem.4c01244
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.4 Å)
Structure validation

227111

数据于2024-11-06公开中

PDB statisticsPDBj update infoContact PDBjnumon